Furthermore, BRAF p.V600E mutation is frequently associated with additional SNVs, including homozygous CDKN2A deletions, that carry the risk of transforming a PLGNT to a higher-grade glioma, specifically in PXAs [29]. Here, CDKN2A is linked to central nervous system cancer.